Curly-tail mice with neural tube defects show abnormal cortical development
© Cains et al; licensee BioMed Central Ltd. 2009
Published: 3 February 2009
Our past work suggests a vital role for cerebrospinal fluid (CSF) in normal cortical development. Abnormal cortical development occurs from the earliest stages following fluid obstruction in the developing brain of a hydrocephalic fetus. Here, we studied development of the cerebral cortex in the curly-tail mouse model of neural tube defects (NTDs). Curly tail litters exhibit a variety of NTDs including exencephaly and spina bifida. A proportion of littermates have no apparent defect.
Materials and methods
Homozygous curly-tail mice were time-mated and injected with 2, bromodeoxyuridine (BrdU, 60 mg/kg) on day E17. Fetuses were harvested on day E19 and fixed in 4% paraformaldehyde. After cryoprotection in 20% sucrose, whole fetuses were sectioned at 25 μm on a Leica cryostat. Sections were air dried before immunocytochemical staining with anti-BrdU antibody (Nova Castro, UK). Images were taken on a Leica DMLB microscope using a Coolsnap camera (Princeton Instruments) and Metaview Software (Universal Imaging).
Curly tail fetuses with exencephaly showed almost total degeneration of the cortex, as a result of exposure of the neuroepithelium to amniotic fluid. Among curly-tail fetuses with a closed brain, all but one showed abnormal migration of BrdU labelled cells. This varied from no apparent migration from the germinal epithelium to a random pattern of stained cells throughout the different zones of the cortex. This compared to the laminar distribution of labelled cells at the top of the cortex, adjacent to the marginal zone, in normal control mice.
While exencephaly is associated with degeneration of the neuroepithelium, mice with a genetic predisposition to neural tube defects show abnormal development of the cerebral cortex, specifically with disturbance of the migration of cells from the germinal zone into the developing cortex.
This article is published under license to BioMed Central Ltd.